ISSN: 2538-2462
January 2022
Vol. 7 No. 1 (2022)
COVID-19 in Myasthenia Gravis: The Double Whammy
Journal of Cellular & Molecular Anesthesia,
Vol. 7 No. 1 (2022),
,
Page 66-69
https://doi.org/10.22037/jcma.v7i1.36574
Abstract
COVID-19 co-infection in patients with myasthenia gravis has not been well described. Our primary aim is to describe the course of illness of a myasthenia patient who developed repeated episodes of myasthenic crisis along with severe COVID-19 infection. This case highlights the need to accurately monitor the immune response to the infection and treatment of myasthenia gravis with COVID-19 should be tailored to the individual patient.
Keywords:
- COVID-19, Myasthenia gravis, Myasthenic crisis
How to Cite
1.
Ashar MS, Soni KD, Singh A, Singh Y, Aggarwal R, Trikha A. COVID-19 in Myasthenia Gravis: The Double Whammy. J Cell Mol Anesth [Internet]. 2021Dec.11 [cited 2022Jul.7];7(1):66-9. Available from: https://journals.sbmu.ac.ir/jcma/article/view/36574
References
1- Ciafaloni E. Myasthenia Gravis and Congenital Myasthenic syndromes. Continuum (Minneap Minn). 2019;25(6):1767–84.
2- Guidon AC, Amato AA. COVID-19 and neuromuscular disorders. Neurology. (2020) 94:959–69. 10.1212/WNL.000000000000956
3- Gilhus NE, Verschuuren JJ. Myasthenia gravis: subgroup classification and therapeutic strategies. Lancet Neurol. 2015;14:1023–36
4- Gilhus NE. Myasthenia gravis. N Engl J Med. 2016;375:2570–2581.
5- Wendell LC, Levine JM. Myasthenic crisis. Neurohospitalist. 2011;1(1):16–22.
6- Jani-Acsadi A, Lisak RP. Myasthenic crisis: guidelines for prevention and treatment. J Neurol Sci. 2007;261:127–133.
7- International MG/COVID-19 Working Group, Jacob S, Muppidi S. et al. Guidance for the management of myasthenia gravis (MG) and Lambert-Eaton myasthenic syndrome (LEMS) during the COVID-19 pandemic. J Neurol Sci. 2020;25:116803.
8- Cao M, Katz S, Simpson Greene E, Davis E, Verma A, Day JW, Wolfe L. Pulmonary Support for Neuromuscular Disease Patients During COVID19 Pandemic.
9- Županić S, Perić Šitum M, Majdak M, Karakaš M, Bašić S, Sporiš D. Case series of COVID-19 in patients with myasthenia gravis: a single institution experience. Acta Neurol Belg. 2021;121(4):1039-1044. doi:10.1007/s13760-021-01662-w
10- Camelo-Filho AE, Silva AMS, Estephan EP, et al. Myasthenia Gravis and COVID-19: Clinical Characteristics and Outcomes. Front Neurol. 2020;11:1053. Published 2020 Sep 11. doi:10.3389/fneur.2020.01053
11- Saied, Z., Rachdi, A., Thamlaoui, S., Nabli, F., Jeridi, C., Baffoun, N., Kaddour, C., Belal, S., & Ben Sassi, S. (2021). Myasthenia gravis and COVID-19: A case series and comparison with literature. Acta neurologica Scandinavica, 144(3), 334–340.
12-Jakubíková M, Týblová M, Tesař A, et al. Predictive factors for a severe course of COVID-19 infection in myasthenia gravis patients with an overall impact on myasthenic outcome status and survival. Eur J Neurol. 2021;28(10):3418-3425.
13-Solé G, Mathis S, Friedman D, et al. Impact of Coronavirus Disease 2019 in a French Cohort of Myasthenia Gravis. Neurology. 2021;96(16):e2109-e2120.
2- Guidon AC, Amato AA. COVID-19 and neuromuscular disorders. Neurology. (2020) 94:959–69. 10.1212/WNL.000000000000956
3- Gilhus NE, Verschuuren JJ. Myasthenia gravis: subgroup classification and therapeutic strategies. Lancet Neurol. 2015;14:1023–36
4- Gilhus NE. Myasthenia gravis. N Engl J Med. 2016;375:2570–2581.
5- Wendell LC, Levine JM. Myasthenic crisis. Neurohospitalist. 2011;1(1):16–22.
6- Jani-Acsadi A, Lisak RP. Myasthenic crisis: guidelines for prevention and treatment. J Neurol Sci. 2007;261:127–133.
7- International MG/COVID-19 Working Group, Jacob S, Muppidi S. et al. Guidance for the management of myasthenia gravis (MG) and Lambert-Eaton myasthenic syndrome (LEMS) during the COVID-19 pandemic. J Neurol Sci. 2020;25:116803.
8- Cao M, Katz S, Simpson Greene E, Davis E, Verma A, Day JW, Wolfe L. Pulmonary Support for Neuromuscular Disease Patients During COVID19 Pandemic.
9- Županić S, Perić Šitum M, Majdak M, Karakaš M, Bašić S, Sporiš D. Case series of COVID-19 in patients with myasthenia gravis: a single institution experience. Acta Neurol Belg. 2021;121(4):1039-1044. doi:10.1007/s13760-021-01662-w
10- Camelo-Filho AE, Silva AMS, Estephan EP, et al. Myasthenia Gravis and COVID-19: Clinical Characteristics and Outcomes. Front Neurol. 2020;11:1053. Published 2020 Sep 11. doi:10.3389/fneur.2020.01053
11- Saied, Z., Rachdi, A., Thamlaoui, S., Nabli, F., Jeridi, C., Baffoun, N., Kaddour, C., Belal, S., & Ben Sassi, S. (2021). Myasthenia gravis and COVID-19: A case series and comparison with literature. Acta neurologica Scandinavica, 144(3), 334–340.
12-Jakubíková M, Týblová M, Tesař A, et al. Predictive factors for a severe course of COVID-19 infection in myasthenia gravis patients with an overall impact on myasthenic outcome status and survival. Eur J Neurol. 2021;28(10):3418-3425.
13-Solé G, Mathis S, Friedman D, et al. Impact of Coronavirus Disease 2019 in a French Cohort of Myasthenia Gravis. Neurology. 2021;96(16):e2109-e2120.
- Abstract Viewed: 64 times
- PDF Downloaded: 66 times
